Blue Water Acquisition Corp. III (BLUWW)
| Market Cap | 331.48M |
| Revenue (ttm) | n/a |
| Net Income | 6.67M |
| EPS | 0.95 |
| Shares Out | 32.31M |
| PE Ratio | 49.71 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,918 |
| Open | 0.4100 |
| Previous Close | 0.4490 |
| Day's Range | 0.4000 - 0.4100 |
| 52-Week Range | 0.0502 - 0.8500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLUWW
Blue Water Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to target businesses in the artificial intelligence, biotechnology, healthcare, and technology sectors. Blue Water Acquisition Corp. III was incorporated in 2024 and is based in Mountainside, New Jersey.
News
Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering
GREENWICH, Conn. , June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and...
Healthcare SPAC Blue Water Acquisition III files for a $200 million IPO
Blue Water Acquisition III, the third blank check company led by the founder of Blue Water Venture Partners targeting healthcare, filed on Thursday with the SEC to raise up to $200 million in an initi...
Blue Water Acquisition III IPO Registration Document (S-1)
Blue Water Acquisition III has filed to go public with an IPO on the NASDAQ
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021
Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.
GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (Nasdaq: BLUW), a special purpose acquisition company (“Blue Water”), today announced that its stockholders have voted ...
A handful of heavily shorted SPACs are being squeezed higher as investors redeem shares ahead of final merger
Most SPACs have redemption rights, which give shareholders the right to sell their shares back to the acquisition company for $10 per share.
Blue Water Acquisition Corp. Announces Change of Special Meeting of Shareholders Date to August 27, 2021
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) (“Blue Water” or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planne...
Blue Water Acquisition Corp. Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Therapeutics, Inc.
GREENWICH, Conn., July 30, 2021 /PRNewswire/ -- Blue Water Acquisition Corp. (Nasdaq: BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced tha...
Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer
NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs...